for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biondvax Pharmaceuticals Ltd - ADR

BVXV.OQ

Latest Trade

2.96USD

Change

-0.01(-0.34%)

Volume

7,709

Today's Range

2.90

 - 

3.00

52 Week Range

2.39

 - 

61.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.97
Open
3.00
Volume
7,709
3M AVG Volume
2.68
Today's High
3.00
Today's Low
2.90
52 Week High
61.50
52 Week Low
2.39
Shares Out (MIL)
11.54
Market Cap (MIL)
43.28
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Biondvax Pharmaceuticals Posts Quarterly Loss Per Share $0.005

Biondvax Announces Third Quarter 2020 Financial Results & Business Update

Biondvax Announces Appointment Of Amir Reichman As New CEO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biondvax Pharmaceuticals Ltd - ADR

BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Industry

Biotechnology & Drugs

Contact Info

Jerusalem Biopark

2Nd Floor, Hadassah Ein Kerem Campus

00000

Israel

+972.8.9302529

http://www.biondvax.com

Executive Leadership

Mark S. Germain

Chairman of the Board

Ron Babecoff

Chief Executive Officer, President, Director

Uri Ben-Or

Chief Financial Officer

Tamar Ben-Yedidia

Chief Scientific Officer

Yisrael Gewirtz

Internal Auditor

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-9.95
Return on Equity (TTM)
-5.16

Latest News

Latest News

BRIEF-BiondVax - Last Of 12,400 Participants Completes Final Visit In Biondvax's M-001 Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

* LAST OF 12,400 PARTICIPANTS COMPLETES FINAL VISIT IN BIONDVAX'S M-001 UNIVERSAL FLU VACCINE PIVOTAL PHASE 3 CLINICAL TRIAL

BRIEF-BiondVax Pharmaceuticals Reports Qtrly Loss Per Share Nis 0.01

* BIONDVAX PHARMACEUTICALS - AS OF MARCH 31, HAD CASH AND CASH EQUIVALENTS OF NIS 42.5 MILLION VERSUS NIS 72.4 MILLION AS OF DECEMBER 31

BRIEF-BiondVax's M-001 Universal Influenza Vaccine Candidate Achieves Primary Endpoints In Phase 2 Trial

* NIH REPORT ON PHASE 2 CLINICAL TRIAL OF BIONDVAX'S M-001 UNIVERSAL INFLUENZA VACCINE CANDIDATE CONCLUDES BOTH PRIMARY ENDPOINTS ACHIEVED

BRIEF-Biondvax's CEO Comments On Impact Of Covid-19 Pandemic On The Company's Ongoing Phase 3 Clinical Trial

* BIONDVAX'S CEO COMMENTS ON IMPACT OF COVID-19 PANDEMIC ON THE COMPANY'S ONGOING PHASE 3 CLINICAL TRIAL

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up